Y-mAbs Therapeutics, Inc. (YMAB)
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States.
It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors.
The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products.
Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
|IPO Date||Sep 21, 2018|
230 Park Avenue
New York, NY 10169
|Phone||646 885 8505|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Thomas Gad||Founder, Interim Chief Executive Officer, President, Head of Business Development and Strategy and Director|
|Bo Kruse||Executive Vice President, Secretary, Treasurer and Chief Financial Officer|
|Dr. Steen Lisby M.D., M.Sc.||Senior Vice President and Chief Scientific Officer|
|Dr. Vignesh Rajah M.B.A., MBBS||Senior Vice President and Chief Medical Officer|
|Joris Wiel Jan Wilms||Senior Vice President and Chief Operating Officer|
|Dr. Torben Lund-Hansen M.Sc., Ph.D.||Senior Vice President and Head of Technical Operations|
|Sue Smith||Senior Vice President and Chief Commercial Officer|
Latest SEC Filings
|Jun 13, 2022||8-K||Current report|
|Jun 2, 2022||8-K||Current report|
|May 31, 2022||8-K||Current report|
|May 26, 2022||8-K||Current report|
|May 19, 2022||8-K||Current report|
|May 19, 2022||4||Statement of changes in beneficial ownership of securities|
|May 9, 2022||10-Q||Quarterly report [Sections 13 or 15(d)]|
|May 9, 2022||8-K||Current report|
|Apr 29, 2022||DEFA14A||Additional definitive proxy soliciting materials and Rule 14(a)(12) material|
|Apr 29, 2022||DEF 14A||Other definitive proxy statements|